LEO 32731 - A Phase I, Single-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs LEO 32731 (Primary)
- Indications Psoriasis
- Focus Adverse reactions
- Sponsors LEO Pharma
- 08 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 15 Dec 2015 Planned End Date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
- 15 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.